Annual Conference

ASBH22 ConfBan 1242x170

Plenary Sessions*

Reframing the Great Resignation in Healthcare 

Thursday, October 27, 11:15 am–12:30 pm
Mary Ersek, PhD RN FPCN; Pringl Miller, MD FACS; Mara Buchbinder, PhD, Moderator 

We have all heard that high numbers of healthcare workers have chosen to leave their jobs during the COVID-19 pandemic. Terms like “Great Resignation” put the focus on the individual who decides to leave, rather than the environment. This panel will focus on the structural issues that have contributed to the departure of healthcare workers, such as racism, sexism, ableism, and other forms of bias and systemic disadvantage that adversely impact healthcare workers, which pre-date the pandemic. Our panelists will offer their perspectives and wisdom on these larger problems and address the role of bioethics and the humanities in thinking about and helping to solve them.    

Decolonizing Data: Restoring Culture and Building Beauty 

Friday, October 28, 11:15 am–12:30 pm
Abigail Echo-Hawk, MA  

This session will focus on ethical data and research techniques that are centered in Indigenous scientific knowledge systems. It will discuss how western based models of achieving health equity have not work for Indigenous communities and must shift to be inclusive of non-western modalities if true equity is to be achieved. An Indigenous framework will be presented that discusses strength-based protective factors and illustrates how to interrupt colonially built health disparities in a manner that benefits tribal communities in rural and urban settings. This framework defies and resists the impacts of ongoing oppression and resulting historical trauma, instead it moves into historical healing which gathers the pieces broken by historical trauma and stitches them back together in bold, beautiful, intricate patterns of strength and resiliency woven on the fabric of Indigenous knowledge and cultural systems.

Doing Bioethics in Public: A Conversation About the Aducanumab Controversy 

Saturday, October 29, 3:15 pm–4:30 pm
Jason Karlawish, MD; Holly Fernandez Lynch, JD MBE  

In June 2021, the FDA approved Biogen’s aducanumab for the treatment of Alzheimer’s disease–and with that, patients and their caregivers finally had a treatment. Or did they? In the months that followed, controversy unfolded over several domains: regulatory capture at the FDA, the difficult balance between speed and certainty, the role of advocacy groups and patient desperation, the relevance of expertise, the distortion of innovation, the cost and coverage of drugs, and more. Join Holly Fernandez Lynch and Jason Karlawish for a conversation about their experiences wading into this controversy and doing bioethics in public.

*All times listed are Pacific Daylight Time (PDT).